HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 1 (2004), Issue 4 (November)

1. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus.
   Obstet Gynecol, 104(5): 1077-85. [Abstract] [Full-text]
2. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.
   Stat Med, 23(21): 3351-63. [Abstract] [Full-text]
3. Erythropoietin is neuroprotective in models of HIV sensory neuropathy.
   Neurosci Lett, 371(2): 102-5. [Abstract] [Full-text]
4. Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus.
   Vaccine, 23(1): 3-13. [Abstract] [Full-text]
5. HIV and hepatitis C virus RNA in seronegative organ and tissue donors.
   Lancet, 364(9445): 1611-2. [Abstract] [Full-text]
6. The multifactorial nature of HIV-1 latency.
   Trends Mol Med, 10(11): 525-31. [Abstract] [Full-text]
7. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes.
   Mol Cell Neurosci, 27(3): 296-305. [Abstract] [Full-text]
8. Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.
   J Am Soc Mass Spectrom, 15(11): 1545-55. [Abstract] [Full-text]
9. Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.
   Virology, 329(2): 465-76. [Abstract] [Full-text]
10. Human immunodeficiency virus 1 favors the persistence of infection by activating macrophages through TNF.
    Virology, 329(2): 371-80. [Abstract] [Full-text]
11. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
    Virology, 329(2): 319-27. [Abstract] [Full-text]
12. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10.
    Virology, 329(2): 302-18. [Abstract] [Full-text]
13. Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation.
    Virology, 329(2): 280-8. [Abstract] [Full-text]
14. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Pediatrics, 114(5): e604-11. [Abstract] [Full-text]
15. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    J Antimicrob Chemother, 54(5): 921-31. [Abstract] [Full-text]
16. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
    J Antimicrob Chemother, 54(5): 915-20. [Abstract] [Full-text]
17. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
    Glycobiology, 14(12): 1229-46. [Abstract] [Full-text]
18. Selection and characterization of peptides specifically binding to HIV-1 psi (psi) RNA.
    Virus Res, 106(1): 77-81. [Abstract] [Full-text]
19. Changes in the human immunodeficiency virus V3 region that correspond with disease progression: a meta-analysis.
    Virus Res, 106(1): 27-33. [Abstract] [Full-text]
20. Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection.
    Eur J Immunol, 34(11): 3208-15. [Abstract] [Full-text]
21. Neurological complications in AIDS patients: the 1-year retrospective study in Chiang Mai University, Thailand.
    Eur J Neurol, 11(11): 755-9. [Abstract] [Full-text]
22. A model system of oral HIV exposure, using human palatine tonsil, reveals extensive binding of HIV infectivity, with limited progression to primary infection.
    J Infect Dis, 190(11): 1989-97. [Abstract] [Full-text]
23. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    J Infect Dis, 190(11): 1979-88. [Abstract] [Full-text]
24. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.
    J Infect Dis, 190(11): 1970-8. [Abstract] [Full-text]
25. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
    J Infect Dis, 190(11): 1962-9. [Abstract] [Full-text]
26. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
    J Infect Dis, 190(11): 1957-61. [Abstract] [Full-text]
27. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
    J Infect Dis, 190(11): 1947-56. [Abstract] [Full-text]
28. Comparison of the sensitivities and viral load values of the AMPLICOR HIV-1 MONITOR version 1.0 and 1.5 tests.
    J Clin Microbiol, 42(11): 5392-3. [Abstract] [Full-text]
29. HIV-1 populations in blood and breast milk are similar.
    Virology, 330(1): 295-303. [Abstract] [Full-text]
30. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
    Virology, 330(1): 271-83. [Abstract] [Full-text]
31. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
    Virology, 330(1): 233-48. [Abstract] [Full-text]
32. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
    Virology, 330(1): 221-32. [Abstract] [Full-text]
33. Influence of CD4+ T cell counts on viral evolution in HIV-infected individuals undergoing suppressive HAART.
    Virology, 330(1): 116-26. [Abstract] [Full-text]
34. Inhibition of certain strains of HIV-1 by cell surface polyanions in the form of cholesterol-labeled oligonucleotides.
    Virology, 330(1): 50-61. [Abstract] [Full-text]
35. Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals.
    Int Immunopharmacol, 4(14): 1829-36. [Abstract] [Full-text]
36. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects.
    Vaccine, 23(2): 205-9. [Abstract] [Full-text]
37. SHIV virus-like particles bind and activate human dendritic cells.
    Vaccine, 23(2): 139-47. [Abstract] [Full-text]
38. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
    Bioorg Chem, 32(6): 536-48. [Abstract] [Full-text]
39. First snapshots of the HIV-1 RNA structure in infected cells and in virions.
    J Biol Chem, 279(46): 48397-403. [Abstract] [Full-text]
40. Mechanistic analysis of pause site-dependent and -independent recombinogenic strand transfer from structurally diverse regions of the HIV genome.
    J Biol Chem, 279(46): 47446-54. [Abstract] [Full-text]
41. Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex.
    J Biol Chem, 279(46): 48224-30. [Abstract] [Full-text]
42. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
    Arch Neurol, 61(11): 1687-96. [Abstract] [Full-text]
43. Recognition of internal cleavage sites by retroviral RNases H.
    J Mol Biol, 344(3): 635-52. [Abstract] [Full-text]
44. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
    Biochemistry, 43(45): 14500-7. [Abstract] [Full-text]
45. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.
    Gene Ther, 11(23): 1703-12. [Abstract] [Full-text]
46. Key references in infectious diseases pharmacotherapy.
    Pharmacotherapy, 24(11): 1586-93. [Abstract] [Full-text]
47. Getting to the bottom of anal itch - a cautionary tale.
    Int J STD AIDS, 15(11): 772-4. [Abstract] [Full-text]
48. Management of HIV-related lymphoma in HIV treatment centres in North Thames Region.
    Int J STD AIDS, 15(11): 765-6. [Abstract] [Full-text]
49. Changing pattern of HIV infection in a tertiary care hospital in New Delhi, India.
    Int J STD AIDS, 15(11): 753-7. [Abstract] [Full-text]
50. Factors associated with sexual problems in HIV-positive gay men.
    Int J STD AIDS, 15(11): 732-6. [Abstract] [Full-text]
51. Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
    J Med Chem, 47(24): 5953-61. [Abstract] [Full-text]
52. Overexpression of a novel lymphocyte population, positive for an intracellular CD14-like antigen, in patients positive for human immunodeficiency virus type 1.
    Clin Diagn Lab Immunol, 11(6): 1040-4. [Abstract] [Full-text]
53. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection.
    Immunity, 21(5): 617-27. [Abstract] [Full-text]
54. Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage.
    J Virol, 78(23): 13315-24. [Abstract] [Full-text]
55. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol, 78(23): 13232-52. [Abstract] [Full-text]
56. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
    J Virol, 78(23): 13163-72. [Abstract] [Full-text]
57. Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes.
    J Virol, 78(23): 13072-81. [Abstract] [Full-text]
58. Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages.
    J Virol, 78(23): 13046-52. [Abstract] [Full-text]
59. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    J Virol, 78(23): 12996-3006. [Abstract] [Full-text]
60. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    J Virol, 78(23): 12975-86. [Abstract] [Full-text]
61. Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach.
    J Virol, 78(23): 12829-37. [Abstract] [Full-text]
62. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.
    J Virol, 78(23): 12800-8. [Abstract] [Full-text]
63. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication.
    J Virol, 78(23): 12735-46. [Abstract] [Full-text]
64. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
    Methods, 34(4): 476-87. [Abstract] [Full-text]
65. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Vaccine, 23(6): 827-39. [Abstract] [Full-text]
66. Longitudinal and cross-sectional studies of HIV-1 RNA and DNA loads in blood and the female genital tract.
    Eur J Obstet Gynecol Reprod Biol, 117(2): 227-35. [Abstract] [Full-text]
67. Non-induced leukocyte extract reduces HIV replication and TNF secretion.
    Biochem Biophys Res Commun, 325(3): 1075-81. [Abstract] [Full-text]
68. Host-dependent serum specificity to the V3 domain of HIV-1.
    Scand J Immunol, 60(5): 471-6. [Abstract] [Full-text]
69. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection.
    J Biol Chem, 279(47): 49055-63. [Abstract] [Full-text]
70. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.
    J Exp Med, 200(10): 1337-46. [Abstract] [Full-text]
71. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells.
    J Exp Med, 200(10): 1279-88. [Abstract] [Full-text]
72. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.
    J Exp Med, 200(10): 1243-56. [Abstract] [Full-text]
73. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    HIV Med, 5(6): 407-14. [Abstract] [Full-text]
74. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
    HIV Med, 5(6): 400-6. [Abstract] [Full-text]
75. Epitope mapping of the phosphorylation motif of the HIV-1 protein Vpu bound to the selective monoclonal antibody using TRNOESY and STD NMR spectroscopy.
    Biochemistry, 43(46): 14555-65. [Abstract] [Full-text]
76. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia.
    J Infect Dis, 190(12): 2181-6. [Abstract] [Full-text]
77. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).
    Psychosomatics, 45(6): 524-35. [Abstract] [Full-text]
78. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Bioconjug Chem, 15(6): 1322-33. [Abstract] [Full-text]
79. Semen parameters of a semen donor before and after infection with human immunodeficiency virus type 1: case report.
    Hum Reprod, 19(12): 2845-8. [Abstract] [Full-text]
80. Evaluation of a school-based intervention for HIV/AIDS prevention among Belizean adolescents.
    Health Educ Res, 19(6): 730-8. [Abstract] [Full-text]
81. The functional interaction between CD98 and CD147 in regulation of virus-induced cell fusion and osteoclast formation.
    Med Microbiol Immunol (Berl), 193(4): 155-62. [Abstract] [Full-text]
82. Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio de Janeiro, Brazil.
    An Acad Bras Cienc, 76(4): 727-41. [Abstract] [Full-text]
83. Hemozoin differentially regulates proinflammatory cytokine production in human immunodeficiency virus-seropositive and -seronegative women with placental malaria.
    Infect Immun, 72(12): 7022-9. [Abstract] [Full-text]
84. Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates.
    J Gen Virol, 85: 3735-45. [Abstract] [Full-text]
85. Optimization of unique, uncharged thioesters as inhibitors of HIV replication.
    Bioorg Med Chem, 12(24): 6437-50. [Abstract] [Full-text]
86. The short cytoplasmic tail of HLA-G determines its resistance to HIV-1 Nef-mediated cell surface downregulation.
    Hum Immunol, 65(11): 1389-96. [Abstract] [Full-text]
87. Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy.
    FEBS Lett, 577(3): 415-21. [Abstract] [Full-text]
88. Development of biosensors with aptamers as bio-recognition element: the case of HIV-1 Tat protein.
    Biosens Bioelectron, 20(6): 1149-56. [Abstract] [Full-text]
89. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients.
    Microbes Infect, 6(14): 1273-7. [Abstract] [Full-text]
90. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I.
    Immunology, 113(4): 524-33. [Abstract] [Full-text]
91. Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
    J Med Virol, 75(1): 59-69. [Abstract] [Full-text]
92. Evaluation of a commercial enzyme immunoassay for HIV screening in urine.
    Eur J Clin Microbiol Infect Dis, 23(11): 831-5. [Abstract] [Full-text]
93. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide.
    Biol Reprod, 71(6): 2037-47. [Abstract] [Full-text]
94. In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer.
    J Biol Chem, 279(48): 50167-75. [Abstract] [Full-text]
95. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.
    Antimicrob Agents Chemother, 48(12): 4864-8. [Abstract] [Full-text]
96. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Antimicrob Agents Chemother, 48(12): 4687-92. [Abstract] [Full-text]
97. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
    Antimicrob Agents Chemother, 48(12): 4680-6. [Abstract] [Full-text]
98. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Eur J Biochem, 271(22): 4594-602. [Abstract] [Full-text]
99. Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors.
    Eur J Biochem, 271(22): 4451-61. [Abstract] [Full-text]
100. Trends in the incidence of acquired immunodeficiency syndrome-related malignancies in Thailand.
     Cancer, 101(11): 2660-6. [Abstract] [Full-text]
101. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase.
     J Biol Chem, 279(49): 51545-53. [Abstract] [Full-text]
102. High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells.
     J Biol Chem, 279(49): 51305-14. [Abstract] [Full-text]
103. Evaluation of the genotypic pattern of HIV-1 resistance in AIDS patients failing antiretroviral therapy.
     Braz J Infect Dis, 8(4): 281-9. [Abstract] [Full-text]
104. Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination.
     J Virol, 78(24): 14066-9. [Abstract] [Full-text]
105. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection.
     J Virol, 78(24): 14053-6. [Abstract] [Full-text]
106. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
     J Virol, 78(24): 14039-42. [Abstract] [Full-text]
107. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.
     J Virol, 78(24): 13934-42. [Abstract] [Full-text]
108. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.
     J Virol, 78(24): 13901-10. [Abstract] [Full-text]
109. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.
     J Virol, 78(24): 13687-96. [Abstract] [Full-text]
110. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china.
     J Virol, 78(24): 13591-9. [Abstract] [Full-text]
111. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
     J Virol, 78(24): 13553-61. [Abstract] [Full-text]
112. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription.
     J Virol, 78(24): 13522-33. [Abstract] [Full-text]
113. Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain.
     J Virol, 78(24): 13409-19. [Abstract] [Full-text]
114. Mutational analysis of the HIV-1 LTR as a promoter of negative sense transcription.
     Arch Virol, 149(12): 2277-94. [Abstract] [Full-text]
115. Evolution of HIV-1-related conjunctival molluscum contagiosum under HAART: report of a bilaterally manifesting case and literature review.
     Graefes Arch Clin Exp Ophthalmol, 242(11): 951-5. [Abstract] [Full-text]
116. Evidence for positive epistasis in HIV-1.
     Science, 306(5701): 1547-50. [Abstract] [Full-text]
117. The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity.
     Virology, 330(2): 481-6. [Abstract] [Full-text]
118. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev.
     Virology, 330(2): 471-80. [Abstract] [Full-text]
119. A modeling approach to the impact of HIV mutations on the immune system.
     Comput Biol Med, 35(1): 1-24. [Abstract] [Full-text]
120. HIV-1 intra-subtype superinfection rates: estimates using a structured coalescent with recombination.
     Infect Genet Evol, 5(1): 85-95. [Abstract] [Full-text]
121. Characteristics of HIV-1 env V3 loop sequences for subtype A1 variant spread in Eastern Europe.
     Infect Genet Evol, 5(1): 45-53. [Abstract] [Full-text]
122. The effect of iron overload on in vitro HIV-1 infection.
     J Clin Virol, 31: S92-8. [Abstract] [Full-text]
123. Limited cross-reactivity between different HIV-1 clades.
     J Clin Virol, 31: S88-91. [Abstract] [Full-text]
124. Small animal model of HIV-1 infection.
     J Clin Virol, 31: S83-7. [Abstract] [Full-text]
125. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
     J Clin Virol, 31: S48-54. [Abstract] [Full-text]
126. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
     J Clin Virol, 31: S26-38. [Abstract] [Full-text]
127. Antigenic complementarity among AIDS-associated infectious agents and molecular mimicry of lymphocyte proteins as inducers of lymphocytotoxic antibodies and circulating immune complexes.
     J Clin Virol, 31: S16-25. [Abstract] [Full-text]
128. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
     J Clin Virol, 31: S7-15. [Abstract] [Full-text]
129. Physical and psychosocial health in family caregiving: a comparison of AIDS and cancer caregivers.
     Public Health Nurs, 21(6): 533-40. [Abstract] [Full-text]
130. Gender differences in factors associated with adherence to antiretroviral therapy.
     J Gen Intern Med, 19(11): 1111-7. [Abstract] [Full-text]
131. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
     J Med Chem, 47(25): 6410-9. [Abstract] [Full-text]
132. New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer.
     J Med Chem, 47(25): 6392-400. [Abstract] [Full-text]
133. Astrocyte specific viral strains in HIV dementia.
     Ann Neurol, 56(6): 873-7. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.